Altre lingue Atai Life Sciences N.V.

Azioni

ATAI

NL0015000DX5

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
2,05 ^USD	-3,76%		+6,22%	+45,39%

24/04	Atai Life Sciences annuncia il dosaggio del primo paziente nella Parte 2 dello studio di Fase 2a di Beckley Psytech, che esplora BPL-003 in aggiunta agli SSRI nei pazienti con depressione resistente al trattamento.	CI
17/04	Atai Life Sciences annuncia la pubblicazione dello studio di Fase 1 di BPL-003 di Beckley Psytech sul Journal of Psychopharmacology	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	25/04
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24/04
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24/04
Clarify Pharma to change name to File Forge Technology	17/04
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17/04
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17/04
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements	08/04
Sector Update: Health Care Stocks Softer Late Afternoon	03/04
Atai Life Sciences Shares Rise Following Maxim Upgrade	03/04
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 in Treatment Resistant Depression	28/03
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28/03
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28/03
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27/03
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27/03
Atai Life Sciences advances VLS-01 for treatment-resistant depression	12/03
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
Atai Life Sciences N : Company Presentation March 2024	04/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Atai Life Sciences N.V.

Azioni

ATAI

NL0015000DX5

Altre lingue

Filtri